Translation of a novel combination therapy approach for non-hodgkin lymphoma . Diffuse large B-cell lymphoma is the most common type of non-hodgkin's lymphoma (NHL) with limited treatment options in…

Active Cooperative Agreement Awarded Last action

Award ID
U01CA272257
Recipient
Awarding agency
Obligated
$3,234,482

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 85% complete
Place of performance
Rochester, MN 55905, USA

Award details come from USAspending.gov.

Description

Translation of a novel combination therapy approach for non-hodgkin lymphoma . Diffuse large B-cell lymphoma is the most common type of non-hodgkin's lymphoma (NHL) with limited treatment options in the relapsed or refractory (R/R) setting. This is true in humans and dogs. Immunotherapy with checkpoint inhibitors (CPIS) have demonstrated durable efficacy for hodgkin's lymphoma, but poor efficacy for NHL. There is an unmet clinical understand mechanisms of immunotherapy resistance and develop therapeutic approaches to improve clinical response for patients with advanced NHL and other cancers. Dlbcl in companion dogs (CDLBCL) is treated with similar chemotherapy protocols and has a similarly poor prognosis in the R/R setting as human dlbcl. While genomic comparison shows limited overlap of the mutational landscape in canine and human dlbcls, preliminary comparison of the tumor microenvironment (TME) shows conservation of stromal and immune compartments between the two species. Thus, cdlblcl provide opportunities to prospectively investigate clinical toxicities and mechanisms of clinical response in a clinically realistic setting that recapitulates the pathology, heterogeneity, and TME of human cancers. Vesicular stomatitis virus (VSV) is a rapidly replicating, robustly immunogenic oncolytic virus (OV) platform that has been engineered for safe systemic therapy of disseminated cancer. Intravenous (IV) VSV therapy was shown preclinically in murine tumor models to rapidly infect, spread within, and kill tumor cells, and induce robust intratumoral immune infiltration, sensitizing tumors to checkpoint blockade. Onix (oncoimmunology accelerator) is a novel, dual targeted CPI that targets both innate and adaptive mechanisms of tumor immune suppression to enhance antitumor immune responses mediated by macrophages and T-cells. We hypothesize that oncolytic VSV and onix will have complementary mechanisms of action (MOA), working in concert to kill tumor cells by direct viral lysis as well as phagocytosis, increase availability of tumor associated antigens (TAAS), promote antigen presentation and activate anti-tumor T-cell responses, to enhance immune mediated tumor killing and improve clinical responses in R/R dlbcl. Our proposal merges the expertise and resources of leading institutions in OV development (mayo clinic), comparative oncology (university of minnesota), and lymphoma immunotherapy (mayo lymphoma spore) to perform a veterinary trial and correlative studies to evaluate the safety and preliminary efficacy of this novel combination therapy in R/R CDLBCL. The proposed studies will yield valuable insights into how an IV administered OV can infect heterogeneous dlbcl tumors and agitate the TME; if this disruption enhances the ability of CPIS (and potentially other immunotherapies) to activate immune mediated tumor killing; and how the tumor architecture differs in the context of clinical response versus non-response. The heterogeneity inherent in naturally occurring CDLBCL will inform the clinical utility of this combination therapy, define MOA, and identify biomarkers that can be explored clinically in human dlbcl.

Transactions

Action Obligated Date
Amendment $67,413
Amendment $0
Amendment $0
Amendment $121,055
Amendment $460,749
Amendment $0
Amendment $114,223
Amendment $643,654
Amendment $0
Amendment $70,432
Amendment $625,851
Original award $584,891
Show all 12

Subawards

Subrecipient Amount Awarded
Regents Of The University Of Minnesota Translation of a novel combination therapy approach for non-Hodgkin lymphoma $67,413
Trustees Of Tufts College $89,657
Regents Of The University Of Minnesota -$40,000
Regents Of The University Of Minnesota A growing body of evidence supports that gut microbiome plays a critical role in a patient’s response to cancer immunotherapy. The goal of the parent U01 is… $121,055
Regents Of The University Of Minnesota SCOPE OF WORK The team of investigators at the University of Minnesota (Drs. Modiano, Borgatti, Sarver, Seelig, and Vallera) will be contribute to the overall… $322,609
Regents Of The University Of Minnesota Translation of a novel combination therapy approach for non-Hodgkin lymphoma . Diffuse large B-cell lymphoma is the most common type of Non-hodgkin’s… $335,904

Quick answers

Who received award U01CA272257?

U01CA272257 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on July 21, 2022.

How much is award U01CA272257 worth?

$3,234,482 has been obligated on U01CA272257.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award